Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Pamela Price

Nurse Practitioner, Family Roanoke, VA Nurse Practitioner

NPI 1346226636 CMS profile 15073

1505 Franklin Rd Sw, Roanoke, VA 24016

Open in the dashboard

General payments

$12,709

243 records reported · program years 2021–2025

Research payments

$5,864

Paid to them · 4 records reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pamela Price of Roanoke, VA is reported in the CMS Open Payments database as having received $12,709 across 243 general payments and $5,864 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,529 53
2024 General $1,492 57
2023 General $3,233 43
2023 Research $2,000 3
2022 General $3,776 52
2022 Research $3,864 1
2021 General $679 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pamela Price
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Pamela Price were reported at $3,529. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Pamela Price Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $679 $124 $35–$379 $132
2022 $3,776 $141 $44–$430 $149
2023 $3,233 $154 $49–$476 $160
2024 $1,492 $165 $51–$504 $164
2025 $3,529 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Pfizer Inc. $5,372 22 payments
  2. Genentech, Inc. $2,845 1 payment
  3. Regeneron Healthcare Solutions, Inc. $1,070 60 payments
  4. AstraZeneca Pharmaceuticals LP $945 48 payments
  5. Genzyme Corporation $917 46 payments
  6. GlaxoSmithKline, LLC. $265 13 payments
  7. Genentech USA, Inc. $179 7 payments
  8. Astellas Pharma US Inc $125 1 payment
  9. Takeda Pharmaceuticals U.S.A., Inc. $121 4 payments
  10. Teva Pharmaceuticals USA, Inc. $115 7 payments
  11. Other $754 34 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,499 231 payments
  2. Consulting Fee $3,895 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,400 2 payments
  4. Honoraria $1,658 2 payments
  5. Education $258 5 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,552 83 payments
  2. DUPIXENT Inflammation And Immunology $932 50 payments
  3. FASENRA $398 16 payments
  4. AIRSUPRA $334 14 payments
  5. TEZSPIRE $320 13 payments
  6. BREZTRI $288 10 payments
  7. NUCALA $265 13 payments
  8. Xolair $179 7 payments
  9. EUCRISA $144 9 payments
  10. DUPIXENT Immunology And Inflammation $137 10 payments
  11. Other $1,336 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Biogen, Inc. $3,864 1 payment
  2. Astellas Pharma Global Development $2,000 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,509

Median for Nurse Practitioner: 389

Drug cost

$181,194

Median for Nurse Practitioner: $21,885

Branded share of claims

27.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Arnuity Ellipta Fluticasone Furoate Brand 117 $37,256
Breo Ellipta Fluticasone/Vilanterol Brand 56 $36,424
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 27 $22,257
Symbicort Budesonide/Formoterol Fumarate Brand 51 $17,831
Qvar Redihaler Beclomethasone Dipropionate Brand 32 $15,389
Advair Hfa Fluticasone Propion/Salmeterol Brand 30 $12,906
Azelastine Hcl Generic 231 $8,050
Ipratropium Bromide Generic 216 $6,635
Epinephrine Generic 38 $5,913
Fluticasone Propionate Hfa Fluticasone Propionate Brand 13 $5,068

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$30,793

Medicare's payments for the services billed

Medicare patients

221

Average age 74

Services billed

1,629

160 women, 61 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 51%
Diabetes 21%
Depression 21%
Osteoporosis 17%
Ischemic heart disease 16%
COPD 15%
Chronic kidney disease 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $313
  • GENZYME CORPORATION $227
$539 — —
NUCALA
  • GlaxoSmithKline, LLC. $178
$178 — —
Hizentra
  • CSL Behring $69
$69 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $67
$67 — —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $54
$54 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

247 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record